Case Studies

Alacrita acts as a life science Professional Employment Organization to ex-US life science companies looking to access the US market.

Challenge: A US medical device company wanted to understand how UK payers would view their technology. They engaged Alacrita to find out.

Alacrita’s radiopharmaceuticals consultants developed an R&D strategy for a major nuclear physics research institute looking to build a capability in nuclear medicine. The project was led by an...

Challenge: A major European venture capital investor needed help to review the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a...

Alacrita's diagnostics consultants were tasked with developing an ex-US business development strategy and identifying sources of non-dilutive finance for a well-funded venture capital funded...

Alacrita Consulting's founders worked together for over 10 years at Onyvax, a London-based cancer immunotherapy company backed by SR One. We have conducted a number of consulting projects in the...

Alacrita’s antibody consultants were engaged to help a start-up company that had developed a suite of proprietary antibody technologies to identify accessible cell surface proteins for discovery of...

Technology Consulting: Novel Antibody Screening Technology Alacrita's antibody consultants were asked to help assess the market potential and develop a commercialization strategy for a novel antibody...

Biologics Consulting: Antibodies to Treat Bacterial Infections An established US biotech company with $bn sales was looking for a team of expert antibody consultants to help them understand the...

Alacrita's radiopharmaceuticals consultant has had a distinguished career in the nuclear medicine industry. For a recent radiopharmaceuticals strategy project for a major public/private investor in a...

Valuations For a biotech company engaged in licensing discussions with a number of major pharmaceutical companies, Alacrita developed rNPV valuations for each program. This 'theoretical' valuation...

Due diligence For a financial investor, Alacrita conducted an IP assessment on a late stage cell therapy investment opportunity. The assessment revealed that the US and EPO patents relied on just...